These results can complicate efforts to use blood results for clinical trial inclusion/exclusion criteria (60), as they suggest that FMRP levels in patients' cortical brain tissue might differ from levels observed in blood, at least for some FXS patients. This evidence concerns the gene FMR1 and fragile X syndrome.